GuidelineDeutsches Arzteblatt international2017
Methamphetamine-Related Disorders.
Guideline in Deutsches Arzteblatt international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Endurance exercise relieves methamphetamine craving behaviors via hepatic synthesis of N-Acetylneuraminic acid.Molecular psychiatry · 2026Article
- Longitudinal brain dynamics and prediction of craving changes in individuals with methamphetamine use disorder.Translational psychiatry · 2026Article
- Neuroimaging Biomarkers in Addiction.medRxiv : the preprint server for health sciences · 2024Article
- Dynamics of intrinsic whole-brain functional connectivity in abstinent males with methamphetamine use disorder.Drug and alcohol dependence reports · 2022Article
- Temporally dynamic neural correlates of drug cue reactivity, response inhibition, and methamphetamine-related response inhibition in people with methamphetamine use disorder.Scientific reports · 2022Article
- A brainnetome atlas-based methamphetamine dependence identification using neighborhood component analysis and machine learning on functional MRI data.Frontiers in cellular neuroscience · 2022Article
- Possible repair mechanisms of renin-angiotensin system inhibitors, matrix metalloproteinase-9 inhibitors and protein hormones on methamphetamine-induced neurotoxicity.Molecular biology reports · 2021Review
- Functional connectivity abnormalities underlying mood disturbances in male abstinent methamphetamine abusers.Human brain mapping · 2021Article
- Associations Between Childhood Trauma and the Age of First-Time Drug Use in Methamphetamine-Dependent Patients.Frontiers in psychiatry · 2021Article
- Current and Emerging Treatments for Methamphetamine Use Disorder.Current neuropharmacology · 2021Review
- Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review.JAMA psychiatry · 2020Review
- Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study.Frontiers in psychiatry · 2020Article
- Role of C/EBP-β in Methamphetamine-Mediated Microglial Apoptosis.Frontiers in cellular neuroscience · 2019Article
- The Consumption of New Psychoactive Substances and Methamphetamine.Deutsches Arzteblatt international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethamphetamine is considered more dangerous than other stimulants because of its acute complications, long-term neurotoxicity, and potential for drug dependence. Until now, there have been no evidence-based guidelines for the treatment of methamphetamine-related disorders, either in Germany or abroad.
methodsA systematic literature search was performed on the treatment of methamphetamine-related disorders. Based on this literature review, a multidisciplinary expert panel developed recommendations using the nominal group technique.
resultsThe evidence base for the treatment of methamphetamine-related disorders is sparse. The efficacy of psychotherapeutic techniques such as cognitive behavioral therapy and contingency management and the efficacy of complex, disorder-specific treatment programs have been proven in ran - domized controlled trials, but it remains unclear which method is best. Persons carrying a diagnosis of substance abuse should be offered psychotherapy. Structured exercise programs, whether self-directed or professionally led, can improve addiction-specific endpoints as well as comorbid disorders and should, therefore, be offered as well. Pharmacotherapy has shown little to no effect in relatively low-quality clinical trials with low case numbers and high dropout rates, and therefore only a few weak recommendations were made. These include tranquilizers for the short-term treatment of agitation and atypical antipsychotics if necessary. Attempts to substitute other substances, such as methylphenidate or dexamphetamine, for methamphetamine have not yielded any robust evidence to date. Sertraline should not be administered due to serious adverse events.
conclusionMany of the recommendations in the guideline are made with a weak grade of recommendation because of the poor evidence base and the modest size of the reported therapeutic effects. In acute situations, symptomoriented treatment is recommended. Psychotherapy and exercise should be offered as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.